NA
IRD

NewEdge Advisors’s Opus Genetics IRD Stock Holding History

NewEdge Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.3K Hold
16,364
– – ﹤0.01% 3047
2026
Q1 		$74.5K Hold
16,364
– – ﹤0.01% 2837
2025
Q4 		$32.9K Hold
16,364
– – ﹤0.01% 3096
2025
Q3 		$27K Hold
16,364
– – ﹤0.01% 3023
2025
Q2 		$15.4K Buy
+16,364
New +$15.2K ﹤0.01% 3042
2024
Q1 		– Sell
-19
Closed -$57 – 3980
2023
Q4 		$57 Buy
+19
New +$56 ﹤0.01% 3663

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NewEdge Advisors's IRD Position: Q2 2026 in Review

NewEdge Advisors held its Opus Genetics (IRD) position steady in Q2 2026 at 16,364 shares worth $67.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3047.

NewEdge Advisors first reported a position in IRD in Q4 2023 and has held it in 6 quarters since. The position peaked at $74.5K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • NewEdge Advisors held 16,364 shares of Opus Genetics worth $67.3K as of Q2 2026.
  • NewEdge Advisors left its Opus Genetics share count unchanged in Q2 2026.
  • Opus Genetics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3047 holding.
  • NewEdge Advisors first reported a position in Opus Genetics in Q4 2023 and has held it in 6 quarters since.
  • NewEdge Advisors's Opus Genetics position peaked at $74.5K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.